

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 19 December 2024- Sareum Holdings plc (AIM: SAR) a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, held its Annual General Meeting ("AGM") today and all resolutions were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the Company by way of proxy.

Details of the proxy voting results are shown in the table below.

Ordinary Resolutions	Votes For	%	Votes Against	%	Votes Total	% of ISC Voted	Votes Withheld
1. Receive the financial statements for the year	11,916,088	99.38	74,805	0.62	11,990,893	9.61%	163,189
2. Receive and approve the Directors' Remuneration Report for the year	11,800,364	98.55	174,011	1.45	11,974,375	9.60%	179,707
3. Re-elect Mr Clive Birch as Director of the Company	10,443,572	92.12	893,439	7.88	11,337,011	9.09%	817,071
4. Re-elect Dr Michael Owen as Director of the Company	10,443,672	92.12	893,339	7.88	11,337,011	9.09%	817,071
5. Re-appoint Shipleys LLP as auditor	11,775,627	98.70	154,926	1.30	11,930,553	9.56%	223,529
6. Authorise the audit committee to determine auditor remuneration	11,856,252	99.29	84,641	0.71	11,940,893	9.57%	213,189
7. Directors' authority to allot new shares	11,538,681	96.23	451,872	3.77	11,990,553	9.61%	163,529
Special Resolution							
8. Directors' authority to disapply pre-emption rights	11,522,085	96.30	442,974	3.70	11,965,059	9.59%	189,023
9. Authority to hold general meetings	11,893,866	99.29	84,805	0.71	11,978,671	9.60%	175,411

The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website (www.sareum.com/investors)

For further information, please contact:

Sareum Holdings plc

Stephen Parker, Executive Chairman

01223 497700

ir@sareum.co.uk

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

020 7409 3494

Oberon Capital (Joint Broker)

Mike Seabrook / Nick Lovering

020 3179 5300

Hybridan LLP (Joint Broker)

Claire Noyce

020 3764 2341

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGFLFIRFRLALIS